Abbott Laboratories (ABT) Covered Calls
Abbott Laboratories is a global healthcare leader that develops, manufactures, and sells a broad line of products across medical devices, diagnostics, nutrition, and generic pharmaceuticals. By 2026, the company has solidified its dominance in cancer diagnostics through the acquisition of Exact Sciences. Abbott is renowned for its market-leading FreeStyle Libre glucose monitors, structural heart technologies, and a robust portfolio of established medicines serving emerging markets.
You can sell covered calls on Abbott Laboratories to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ABT (prices last updated Mon 4:16 PM ET):
| Abbott Laboratories (ABT) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 112.65 | +3.09 | 111.80 | 112.70 | 13.6M | 30 | 190 |
| Covered Calls For Abbott Laboratories (ABT) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 113 | 1.74 | 110.96 | 1.6% | 48.7% | |
| Apr 17 | 115 | 2.66 | 110.04 | 3.0% | 27.4% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Abbott operates a resilient, diversified business model that minimizes reliance on any single healthcare sector. By 2026, the company has pivoted heavily toward precision diagnostics and chronic disease management. Their primary segments include:
- Medical Devices: The company's fastest-growing division, led by the FreeStyle Libre continuous glucose monitoring (CGM) system and advanced "structural heart" solutions like the TriClip and Aveir leadless pacemakers.
- Diagnostics: Enhanced by the 2026 acquisition of Exact Sciences, this segment now leads in cancer screening with the Cologuard and Oncotype DX platforms, alongside its Alinity core laboratory systems.
- Nutrition: A world leader in pediatric and adult nutrition, featuring brands like Similac and Ensure, which are undergoing a "strategic volume reset" in 2026 with eight new product launches.
- Established Pharmaceuticals (EPD): A portfolio of high-quality branded generic medicines specifically tailored for high-growth emerging markets in Asia, Latin America, and the Middle East.
Competitive Landscape
Abbott competes against specialized medical technology firms and diversified healthcare conglomerates. In the diabetes and heart health sectors, its most direct rivals are Medtronic and Dexcom. In the diagnostics space, it faces stiff competition from Danaher and Thermo Fisher Scientific. Within the nutrition and pharmaceutical markets, it encounters global giants such as Nestlé and Pfizer. Despite these rivals, Abbott’s "cradle-to-grave" healthcare ecosystem and its status as a Dividend King provide a competitive moat that is difficult to replicate.
Strategic Outlook and Innovation
Abbott’s 2026 strategy is defined by "The Great Diagnostic Pivot," shifting from pandemic-era testing to oncology and early cancer detection via the Exact Sciences integration. A major focal point is AI-Driven Bio-Wearables, with the rollout of the Lingo consumer biowearable and a new dual-analyte sensor that tracks both glucose and ketones. In the surgical space, Abbott is advancing Pulsed Field Ablation (PFA) via the Volt system to treat atrial fibrillation with greater precision. Management has issued a bullish 2026 outlook, targeting 7% organic sales growth as the Nutrition segment recovers and new Medical Device approvals reach full commercial scale. By maintaining a disciplined R&D pipeline and leveraging its vast global distribution network, Abbott aims to remain the primary orchestrator of data-driven, personalized healthcare delivery.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | KSS covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | OWL covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? ABR Covered Calls | ABUS Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
